Available EU DMF/CEP
EU DMF
CEP
API Status
Commercial
Pipeline
Therapeutic Category
Alimentary tract & metabolism
Anti-infectives for systemic use
Antipyretic, analgesic and anti-inflammatory
Antineoplastic & immunomodulating agents
Blood & blood forming organs
Cardiovascular system
Genito-urinary system & sex hormones
Injectable forms
Musculo-skeletal system
Nervous system
Opthalmological preparations
Respiratory system
Available US DMF
US DMF
Additional DMF
Japanese DMF
Chinese DMF
Korean DMF
Injectable Forms
Yes
No

Oxcarbazepine

CAS No.

28721-07-5

Reference product

Trileptal/novartis

Polymorphic form

Form A

Therapeutic Area

Nervous system

Status

Commercial

EU DMF readiness

US DMF readiness

Drug description:

Oxcarbazepine belongs to antiepileptic medications.
Oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and as monotherapy in the treatment of partial seizures in pediatric patients aged 4 years and above with epilepsy, and as adjunctive therapy in pediatric patients aged 2 years and above with partial seizures.
It is formulated as an oral extended-release tablet, immediate-release tablet, suspension.

Mechanism of action:

The pharmacological activity is primarily exerted through the 10-monohydroxy metabolite (MHD) of Oxcarbazepine. Oxcarbazepine and MHD produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyper excited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. These actions are important in the prevention of seizure spread in the intact brain. In addition, increased potassium conductance and modulation of high-voltage activated calcium channels may contribute to the anticonvulsant effects of the drug. No significant interactions of oxcarbazepine or MHD with brain neurotransmitter or modulator receptor sites have been demonstrated.

Disclaimer
Products protected by valid patents are not offered for commercial sale in countries where the sale of such products constitutes patent infringement but are offered solely for uses reasonably related to the development and submission of information under a law regulating the manufacture, use or sale of drugs. It is within the buyer’s responsibility and liability to check the patent situation of the product in the imported market(s).

OK